Wire · founder news, decoded · opportunities
FDA panel loosens restrictions for controversial peptides popular online
◆ Published
23 July 2026
◆ Topic
opportunities
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 July 2026 · Fusion42 review
An FDA advisory panel voted to loosen restrictions on unregulated peptides like BPC-157 and TB-500, allowing compounding pharmacies to produce them despite lack of clinical human trials. Health Secretary RFK, a vocal proponent, has signalled intent to reverse Biden-era restrictions on the growing online wellness market.
This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.
◆ The Wire takeaway
If you're building a telehealth, supplement, or wellness platform, you now have a legal route to peptide sales that didn't exist last month. The FDA panel's vote opens compounding pharmacies as your distribution layer, and RFK's presence in government means this deregulation will likely stick.
◆ Related on Wire
- FDA Weighs Peptide Regulation Amid Safety Concerns23 July 2026
- FDA panel reviewing some peptides to consider loosening regulations for unapproved therapies23 July 2026
- FDA panel votes to place popular peptide BPC-157 on compounding list23 July 2026
- FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list23 July 2026
- FDA peptide review could lead to new compounding boom23 July 2026
- An FDA Committee Just Voted in Favor of Peptides—Despite the Agency's Opposition23 July 2026
◆ Topics
Digital Health · peptides · fda-regulation · compounding-pharmacy · biotech · wellness-market · deregulation